esmo summit middle east 2018€¦ · esmo summit middle east 2018 clinical case presentation...
TRANSCRIPT
![Page 1: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/1.jpg)
ESMO SUMMIT MIDDLE EAST 2018Clinical Case Presentation
Shailesh V. Shrikhande, MS, MD, FRCS (Hon)
Chief, GI and HPB Surgery
Professor & HOD Surgical Oncology
Tata Memorial Centre, Mumbai, India
6-7 April 2018, Dubai, UAE
![Page 2: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/2.jpg)
CONFLICT OF INTEREST DISCLOSURE
Honorarium received by Tata Memorial Hospital
Covidien, IRCAD Meeting 2016, Taiwan
Johnson & Johnson, Gastric Advisory Council 2015, Seoul, Korea
Merck Serono, Asia Pacific mCRC Meeting 2015, Singapore
![Page 3: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/3.jpg)
EXPERT PANEL
Josep Tabernero, Medical Oncologist
Marwan Ghosn, Medical Oncologist
Syed M. Hasnain, Radiation Oncologist
Mohsen Mokhtar, Medical Oncologist
Eric Van Cutsem, Medical Oncologist
Fortunato Ciardiello, Medical Oncologist
![Page 4: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/4.jpg)
CASE 1: HISTORY (OCTOBER 2016)
50 year old gentleman
Diabetic on Rx – 5 yrs
Presented with abdominal pain – 1 month
H/o 10 kg LOW – over 3 months
Clinical examination
Vitals stable, no icterus
ECOG 1
PA - large palpable mass 8x6 cm in Right hypochondrium
PR - no growth
![Page 5: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/5.jpg)
EVALUATION
USG abdomen and pelvis:
Large GB mass infiltrating liver
Hb: 16 gm%
Liver Functions:
Bilirubin 0.5 mg%
Albumin 4.3 mg%
Liver Enzymes - WNL
![Page 6: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/6.jpg)
ROLE OF TUMOR MARKERS?
S. CA 19.9 : 44960.0 units
S. CEA: 169.71 units
![Page 7: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/7.jpg)
TUMOR MARKERS
CEA: Specificity 90%; Sensitivity only 50% when used for screening
CA 19-9: Sensitivity and specificity 75%
Minimal clinical value compared with clinical awareness but useful for follow up
![Page 8: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/8.jpg)
NEXT MODE OF EVALUATION?
A. Contrast enhanced CT scan
B. MRI
C. PET
![Page 9: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/9.jpg)
INVESTIGATIONS
CECT abdomen (October 2016)
Large enhancing lesion involving GB & extending into liver seg IVa, IVb & V
Loss of fat plane with hepatic flexure of colon
Multiple portal & portocaval nodes largest 1.7 X 1.5cm
Solitary pulmonary millimetric nodule in right upper lobe ant seg - indeterminate
![Page 10: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/10.jpg)
ROLE OF PET SCAN?
![Page 11: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/11.jpg)
LOF plane with duodenum and
colon
Enhancing mass lesion in
relation to GB fossa
Peripherally Enhancing lesion Central necrosis
![Page 12: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/12.jpg)
PET CT (25.11.2016)
Peripherally enhancing centrally necrotic bulky soft tissue mass measuring 6.9 x
6.1 x 7.3 cm is noted in the right lobe of liver
Loss of fat planes with hepatic flexure and duodenum with perilesional nodules
GB cannot be differentiated separately from the mass
Low grade FDG avid peripancreatic and portocaval nodes are noted measuring 9
mm with a max SUV of 6.52
![Page 13: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/13.jpg)
ROLE OF STAGING LAPAROSCOPY?
A. YES
B. NO
![Page 14: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/14.jpg)
STAGING LAPAROSCOPY
Most CA GB patients do not require palliative operations, and incidence of
occult metastatic disease is high and hence staging laparoscopy makes
sense
Yield is as high as 48% (Weber et al, 2002)
Even in patients who had prior simple cholecystectomy, yield is as high as
20% and is indicated
![Page 15: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/15.jpg)
STAGING LAPAROSCOPY (16.11.2016)
No evidence of peritoneal / omental liver metastases
Hepatic flexure of colon and duodenum adherent to GB; no frank infiltration
![Page 16: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/16.jpg)
MANAGEMENT PLAN ?
A. Radical Curative Surgery
B. Neoadjuvant chemotherapy and reassess for Surgery
C. Neoadjuvant chemoradiotherapy and reassess for Surgery
D. Palliative treatment options
![Page 17: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/17.jpg)
DO WE NEED A BIOPSY?
USG guided GB mass (03.11.2016)
Moderately differentiated adenocarcinoma
![Page 18: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/18.jpg)
![Page 19: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/19.jpg)
ROLE OF CHEMOTHERAPY AND RADIOTHERAPY IN
GB CANCERS
Is there any strong evidence or recommendation ?
Should we routinely use neoadjuvant treatment in Ca GB ?
What are the indications for neoadjuvant treatment?
![Page 20: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/20.jpg)
ON-GOING TRIAL AT TATA MEMORIAL
In POLCA-GB trial - CTRT arm (NCT02867865)
Received EBRT to GB tumor mass to a dose of 52Gy/25#/35 days - SIB technique
Remaining PTV 45gy/25# using 6MV photons with Intensity Modulated Arc technique from
6/12/16 to 9/1/17
Along with 5 cycles of concurrent Gemcitabine on 06-12-2016, 13-12-2016, 20-12-2016, 27-
12-2016 and 03-01-2017.
![Page 21: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/21.jpg)
Received 2# Gem - Cis (LD 21.2.2017)
CT Abdomen (14.03.2017)
Residual lesion in GB fossa with liver infiltration- SD
Episode of hematemesis on 9th March at home
UGI Endoscopy (11.03.2017)
Acute ulcer in the bulb of duodenum
![Page 22: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/22.jpg)
UGIE (07/04/17)
Diffuse erythema in antro-pyloric region
Small superficial ulcer 0.5 x 0.5 with clean base in pre-pyloric region
Duodenum: D1 and D1-D2 junction showed infiltrated mucosa and erythema.
D2-Normal. No active bleeding.
Response assessment PET (12/04/2017)
Significant decrease in the size and metabolic activity of the GB fossa mass and LN with
residual viable disease; Metabolic activity of Right SCF node
Right SCF FNAC
Necrotizing granulomatous inflammation, suggestive of tuberculosis.
Malignant cells not seen
![Page 23: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/23.jpg)
FURTHER PLAN?
A. Continue chemotherapy
B. Assess for Surgery
![Page 24: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/24.jpg)
Started on ATT (April 2017)
After 1 month of ATT posted for Surgery
Plan:
Radical Cholecystectomy with Distal Gastrectomy
![Page 25: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/25.jpg)
Underwent Radical Cholecystectomy with Distal Gastrectomy, D1 resection with
ante-colic Gastro-jejunostomy on 12.05.17
Intraoperative findings
➢GB mass fistulized in D1
➢No colonic involvement
➢Peri-portal and porto-caval nodes
➢Inter-aortocaval nodes negative on FS
Recovered uneventfully except for serous discharge with prolonged drain for 2 weeks
![Page 26: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/26.jpg)
HISTOPATHOLOGY
No residual viable tumor
Cystic duct margin: free of tumor
Gastric and duodenal margin: free of tumor
Lymph nodes: 6 negative nodes
![Page 27: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/27.jpg)
ADJUVANT TREATMENT
3# Gemcitabin + Cisplatin
![Page 28: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/28.jpg)
ABC 02 TRIAL
![Page 29: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/29.jpg)
ADJUVANT CAPECITABINE FOR BILIARY TRACT CANCER:
THE BILCAP RANDOMIZED STUDY.
Conclusion:
Cape improves OS in BTC when used as adjuvant and should become standard of care.
![Page 30: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/30.jpg)
FOLLOW UP
Asymptomatic at last follow up
Normal tumor markers
USG A+P: No e/o disease
![Page 31: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/31.jpg)
Future Oncology 2015
![Page 32: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/32.jpg)
HPB 2018 (ARTICLE IN PRESS)
CHAUDHARI V, SHRIKHANDE SV, GOEL M ET AL.
OUTCOME OF NEOADJUVANT CHEMOTHERAPY IN “LOCALLY ADVANCED/BORDERLINE
RESECTABLE” GALLBLADDER CANCER: THE NEED TO DEFINE INDICATIONS.
Proposes clinico-radiologic criteria to define borderline resectable / locally advanced GBC
160 consecutive patients (2010 to 2016)
Chemotherapy with neoadjuvant intent in locally advanced/borderline resectable GBC showed
good response rates (clinical benefit rate 70%)
Curative surgical resection or disease stabilisation in significant number of patients (66/160)
Definitive surgery after favourable response to NACT results in good survival.
![Page 33: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/33.jpg)
TATA MEMORIAL HOSPITAL CRITERIA FOR BR / LA GBC • TUMOUR
• (T3-T4 tumours)
• Contiguous Liver involvement > 2cm
• Involvement of bile duct causing obstructive jaundice
• (Type I/II block on MRCP/ERCP/PTBD)
• Radiological / Endoscopic involvement of antropyloric region of stomach, duodenum, hepatic flexure of colon or small intestine
• NODE
• (N1 station)
• Radiological suspicion of lymph node involvement N1 - Hepatic artery (Station 8), Hepatoduodenal ligament (Station12), Retro
pancreatic / retroduodenal (Station 13)
• Size > 1cm in short axis, round in shape, and heterogenous enhancement on CT/PET scan.
• VASCULAR
• (T4 tumours)
• Impingement/ involvement (<180-degree angle) of one or more of the following blood vessels:
• Common Hepatic Artery and Right & Left Hepatic artery
• Main Portal vein and Right & Left Portal vein
• FOR INCIDENTAL GBC
• Residual/Recurrent mass in GB fossa /liver bed
• N1 nodes as per nodal criteria.
• Involvement of bile duct causing OJ (Type I/II Block)
![Page 34: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/34.jpg)
CASE 2: HISTORY
62 year / Male / ECOG 1
Recently diagnosed diabetic
Presented with abdominal pain 2 months
O/E
GC: Good
No Pallor / Icterus / SCLN
PA: Soft, no mass
![Page 35: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/35.jpg)
INVESTIGATIONS
Liver Function Tests
Bilirubin 0.8 mg%
Albumin 4.4 mg%
AST/ALT 14 / 15
Hb: 14.6 gm%
USG abdomen: Pancreatic mass
![Page 36: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/36.jpg)
ROLE OF TUMOR MARKERS IN PANCREATIC CANCER
CEA: 7.5 units
CA 19-9: 911 units
![Page 37: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/37.jpg)
NEXT MODE OF EVALUATION
A. Contrast enhanced CT scan (CECT)
B. MRI
C. PET
D. EUS
![Page 38: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/38.jpg)
MDCT PANCREATIC PROTOCOL, NCCN (2016)
![Page 39: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/39.jpg)
Hypodense mass at
pancreatic neck
![Page 40: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/40.jpg)
Collaterals at
SMV-SV junction
SMV-SV
confluence
involved
Hypodense
mass at neck
of pancreas
Distal SMV stump
available for
reconstruction
![Page 41: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/41.jpg)
MDCT (08.08.2016)
Hypodense mass 2.6 x 2.6 cm at pancreatic neck
Encasing distal most part of SMV and proximal 9 mm of PV near the confluence,
with significant luminal narrowing
Portal vein mildly dilated (15 mm at Porta), few dilated portosystemic collaterals,
Splenic vein not encased
The lesion abuts the common hepatic artery and SMA
No significant LN, no distant metastases
![Page 42: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/42.jpg)
ROLE OF STAGING LAPAROSCOPY?
A. Yes
B. No
Indications
CA 19-9 > 1000
Pancreatic body mass > 4 cm
![Page 43: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/43.jpg)
ROLE OF BIOPSY
EUS guided biopsy?
USG guided FNAC
Adenocarcinoma
![Page 44: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/44.jpg)
WITH THIS INFORMATION….
Is it,
A. Resectable?
B. BRPC?
C. LAPC?
![Page 45: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/45.jpg)
With regard to the porto-venous axis, any degree of
involvement falls into the category of borderline resectable
disease as long as the vein can be technically resected and
reconstructed
![Page 46: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/46.jpg)
BRPC: MANAGEMENT PLAN?
A. Upfront Surgery
B. NACT and reassess for Surgery
C. NACT/RT and reassess for Surgery
![Page 47: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/47.jpg)
BORDERLINE RESECTABLE:
NACT VS NACT/RT, RESULT OF 3 META-ANALYSIS
![Page 48: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/48.jpg)
Neoadjuvant Therapy in BRPC: Systematic Review and Meta-Analysis
63% pts resected
87% R0
Median OS 25.9 months (resected)
FOLFIRINOX
(n=64)
Gem-based
Resection
rate
72% 67%
R0 60% 58%
G3 /4 Toxicity 53% 30%
Tang K. Pancreatology 2016;16: 28-37
![Page 49: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/49.jpg)
Toxicity
Grade 3 & 4 toxicity 37.3%
Tang K. Pancreatology 2016;16: 28-37
![Page 50: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/50.jpg)
Plan:
NACT and reassess
Received 4# FOLFIRINOX
![Page 51: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/51.jpg)
POST NACT: REASSESSMENT
CECT Scan
• Partial Response
• SMV appears encased up to 2.3 cm near portal
confluence
• Splenic vein encased near confluence up to
length of 1.6 cm
• Main PV appears partially encased for 2 cm
![Page 52: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/52.jpg)
Disease at neck
with SMV SV
junction involved
![Page 53: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/53.jpg)
S. CA 19.9 611 units
S. CEA 6.75 units
PLAN : Pylorus preserving / Classical pancreaticosplenectomy with portal
vein confluence resection with SOS PTFE Graft reconstruction (28.12.16)
![Page 54: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/54.jpg)
INTRAOPERATIVE FINDINGS
Tumor involving the head, neck and body of pancreas
Encasement of the PV, SMV and the SMV - PV junction
The SMA adventitia was involved and was resected from the SMA
No omental, peritoneal or liver deposits.
![Page 55: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/55.jpg)
PANCREATIC HEAD, NECK AND BODY WAS INVOLVED
SMV looped
![Page 56: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/56.jpg)
RADICAL TOTAL PANCREATECTOMY SPECIMEN
![Page 57: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/57.jpg)
ISGPS, TYPE III PORTAL VEIN RESECTION
![Page 58: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/58.jpg)
POSTOPERATIVE TUMOR BED
![Page 59: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/59.jpg)
HPR: CAN YOU ELABORATE ON IMPORTANCE OF EACH AS
PROGNOSTICATION ?
WHAT IS ADEQUATE LYMPHADENECTOMY IN CA PANCREAS ?
ROLE OF EXTENDED RESECTIONS IN CA PANCREAS ?
IS THERE ANY ROLE OF ARTERIAL RESECTIONS ?
MDAC; ypT3N0
LVI +
PNI+
Retroperitoneal/SMA surface involved
0/24 Nodes
![Page 60: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/60.jpg)
Post op period:
Uneventful recovery
Received 6# single agent Gemcitabine
![Page 61: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/61.jpg)
FOLLOW UP
Developed B/L multiple liver metastases recently
![Page 62: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/62.jpg)
• In the intention-to-treat analysis, the 1-YSR and 2-YSR in the neoadjuvant treatment group
(74% and 41%) were nearly twice as high as in the upfront surgery group (48% and 26%)
• In the PP1 and PP2 analysis, there was no difference in the 2-YSR between the groups
Jang J, et al. Ann Surg 2018
![Page 63: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/63.jpg)
In 44% of pCR patients, no recurrence or death was observed.
Median OS 27 months; in pCR group median OS
was not yet met at 60 months; patients without a
pCR 26 months
pCR , a negative lymph node status
and neodjuvant FOLFIRINOX
independent predictors of OS
He J, et al. Ann Surg 2018
![Page 64: ESMO SUMMIT MIDDLE EAST 2018€¦ · ESMO SUMMIT MIDDLE EAST 2018 Clinical Case Presentation Shailesh V. Shrikhande, MS, MD, FRCS (Hon) Chief, GI and HPB Surgery Professor & HOD Surgical](https://reader035.vdocument.in/reader035/viewer/2022070707/5eaab9f37377d52fa94f87e9/html5/thumbnails/64.jpg)